$APGE

JONES WILLIAM A JR sold (to issuer) 34,824 shares of APGE

JONES WILLIAM A JR sold (to issuer) 34,824 shares of Apogee Therapeutics, Inc. (APGE) on 2026-09-03.

Original reporting
SEC EDGAR · JONES WILLIAM A JR
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$APGE
Neutral
medium confidence
Mentioned
$APGE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APGENeutralLow
01

Why it matters

The director's complete exit may be noted by investors but lacks material size to drive price moves.

02

Market read

Low relevance; small insider sale with no price disclosed.

03

What to watch

Potential tax-driven sale or portfolio rebalancing; lack of price data limits interpretation.

Relevance 4/10Novelty 4/10Timing: same day filing 2026-09-03

Background

Form 4 filing reports insider transactions; directors must disclose sales.

Company-level read

Ticker impact

$APGENeutralMedium confidence
Context

Director William Jones sold 34,824 shares, leaving zero holdings after the transaction.

Expected impact

Limited short-term impact; potential slight downward pressure.

Evidence & confidence

The sale size is small relative to typical float and no price information is provided, reducing actionable insight.

Market effects

Minimal effect on biotech sector; insider activity is routine.

No regional impact.

Not globally relevant.

Counterpoint

Sale could be unrelated to company outlook; may not indicate negative sentiment.

Key entities

  • Apogee Therapeutics, Inc.

    Biopharmaceutical company developing therapies for rare diseases.

  • William Jones A Jr.

    Director of Apogee Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABBVHighAI 9/10

Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?

AbbVie (ABBV) completed its $10.9B acquisition of Apogee Therapeutics (APGE) at $135.11 per share. AbbVie also reported positive Phase 3 trial results for etentamig. Q2 2026 revenue for AbbVie rose 10.2% to $16.99B, with adjusted EPS up 22.9% to $3.65. Apogee reported a net loss of $85.9M in Q2 2026. Hedge funds increased stakes in both companies ahead of the deal.

$ABBVHighAI 9/10

AbbVie Completes $10.9 Bln Acquisition Of Apogee Therapeutics

AbbVie (ABBV) completed its $10.9 billion acquisition of Apogee Therapeutics (APGE), paying $135.11 per share. The deal strengthens AbbVie's immunology pipeline, including Apogee's lead asset, zumilokibart, for atopic dermatitis. AbbVie expects the acquisition to be dilutive to earnings until 2032. AbbVie reaffirmed its 2026 EPS guidance of $13.87-$14.07, including a $0.14 per-share dilutive impact. ABBV closed at $261.72, up 0.67%.

$MMEDMed

Biotech Stocks At 52-Week Highs - MMED +10%, PLSE, SOLV, RPRX, APGE

Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.